Latest filing published 13 May 2022 for Oncology Institute, Inc., €7.7M.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Richy Agajanian: trading record in brief
This profile gathers the share dealings of Richy Agajanian in Starling Oncology, Inc., where the filings describe the role as chief executive. Altogether 2 filings, all relating to 11 May 2022.
Sales make up the whole of the open-market record (2 sales, €9.1M).
The record was last updated on 13 May 2022 with an open-market sale (€1.4M) in Starling Oncology, Inc. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Richy Agajanian
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,346,565 shares@ US$6.00100.0% of flowClass A Common StockSEC:0001437749-22-012393:0
1 of 1 declaration
